Celecoxib plus standard chemo for CD5+ DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with CD5-positive diffuse large B-cell lymphoma (a specific subtype of a common lymphoma) and have not received any treatment for it yet.
- Your lymphoma is stage III or IV (advanced) and you have at least one tumor that can be measured on scans.
- You are in generally good health (able to care for yourself) and your heart, liver, kidney, and blood cell counts are within acceptable ranges.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a new drug called TRS005 combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) for people who haven't yet been treated for a type of lymphoma called CD20-positive DLBCL. The goal is to see if adding TRS005 helps more people get better.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a way to use your tumor's DNA (called ctDNA) to choose a targeted treatment for your newly diagnosed DLBCL. It aims to see if this personalized approach works better than standard care.
This study tests whether adding celecoxib (an anti-inflammatory drug) to standard immunotherapy and chemotherapy improves outcomes for people with a specific type of bile duct cancer that has high levels of a protein called CK5/6. It aims to see if the combination is safe and effective.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.